uniQure annuncia un aggiornamento sugli studi clinici di fase I/II della terapia genica AMT-130 per il trattamento della malattia di Huntington

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients Leggi tutto...

it_ITItalian